Siemens Healthineers AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bernhard Montag
- Full Time Employees
- 74,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Siemensstr. 3 Forchheim BV Germany 91301
- IPO Date
- May 14, 2018
- Website
- siemens-healthineers.com
- Similar Companies
- Business
- Siemens Healthineers AG operates as a leading global medical technology company specializing in the development, manufacturing, and sale of a broad spectrum of diagnostic and therapeutic products and services in healthcare. Its core business segments include Imaging, which offers magnetic resonance imaging (MRI), computed tomography (CT), X-ray systems, molecular imaging, and ultrasound systems; Diagnostics, providing laboratory diagnostics, point-of-care testing, and molecular diagnostic products; the Varian segment, delivering innovative multi-modality cancer care technologies and integrated oncology solutions; and Advanced Therapies, which offers image-guided minimally invasive treatment products including angiography systems, mobile C-arms, and robotic-assisted platforms for cardiovascular and peripheral vascular interventions. The company also provides clinical education, asset management, consulting, and digital health services. Siemens Healthineers operates globally, with significant presence in the U.S., Europe, and other key healthcare markets. Founded in 2017 and headquartered in Erlangen, Germany, it serves healthcare providers worldwide. In the recent 1-2 years, Siemens Healthineers has significantly expanded its molecular imaging and radiopharmaceutical capabilities by acquiring Advanced Accelerator Applications Molecular Imaging from Novartis in December 2024. This acquisition extended its PETNET Solutions network by adding 13 manufacturing sites across France, Spain, Portugal, Italy, Germany, and product distribution into Switzerland, enhancing its portfolio in diagnostic radiopharmaceuticals and theranostics, a personalized cancer treatment approach. Furthermore, Siemens Healthineers launched advanced imaging innovations such as the Luminos Q.namix fluoroscopy and radiography platform at RSNA 2024, designed to improve workflow efficiency with integrated AI support and ergonomic operation. The company continues to invest in expanding production capacity and boosting innovation, including a $150 million investment in the U.S. to better serve customers. It also focuses on integrating AI-powered technologies for enhanced imaging and personalized care pathways, exemplified by recent product launches and enhancements in cancer care imaging with Varian's HyperSight technology, which significantly improves image resolution and treatment precision. Siemens Healthineers operates under Siemens Aktiengesellschaft as a publicly listed subsidiary, maintaining a strong footprint in advanced medical technology markets through continuous innovation, strategic acquisitions, and expansion in diagnostics, imaging, and therapeutic solutions. This comprehensive profile reflects Siemens Healthineers' position as a diversified and innovation-driven medical technology company with extensive global operations and recent strategic enhancements in molecular imaging, digital health, and personalized cancer treatment technologies.
Siemens Healthineers AG (SMMNY) Discusses Q3 Pre-Close Updates: Foreign Exchange and Tariff Impacts on Revenue and Earnings Prepared Remarks Transcript
AiM Medical Robotics Announces Collaboration Agreement with Siemens Healthineers to Advance MRI-Guided Robotic Neurosurgery
Siemens Healthineers: Update Post The Carve-Out Announcement
Siemens Healthineers cuts 2026 outlook
Siemens Healthineers: Razor-And-Blades Model On A China-Driven Dip
CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results
Siemens Healthineers AG (OTCMKTS:SMMNY) Receives Average Rating of “Buy” from Brokerages
Siemens plans shareholder vote on Siemens Healthineers spin-off in February 2027
Siemens Healthineers AG (SMMNY) Discusses Q2 Pre-Close Outlook With Focus on Foreign Exchange and Tariff Headwinds Prepared Remarks Transcript
Siemens Healthineers AG (OTCMKTS:SMMNY) Receives Average Rating of “Buy” from Analysts
Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue
Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available
Ki Reply and Data Reply Lay the Strategic Foundation for AI Innovation at Siemens Healthineers with “Cerebra”
Siemens Healthineers AG (OTCMKTS:SMMNY) Given Average Rating of “Buy” by Analysts
Siemens Healthineers AG (SMMNY) Q1 2026 Earnings Call Transcript
Siemens Healthineers Core Businesses Offset Currency, Tariff Challenges
Siemens Healthineers beats Q1 profit estimates on strong imaging unit margins
Siemens Healthineers: Potentially Much Stronger Than Siemens In 2026E
Siemens Healthineers AG (SMMNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Siemens Healthineers AG (SMMNY) Analyst/Investor Day Transcript